Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCD411 vs Eylea in Wet Age-related Macular Degeneration
NCT04480463Phase 3Completed
- Sponsor
- Sam Chun Dang Pharm Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Sep 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 14
01
Overview
A Phase 3 trial of SCD411 in neovascular age-related macular degeneration (NVAMD), sponsored by Sam Chun Dang Pharm Co., Ltd.. Started Aug 2020; status: completed.
02
Drugs
SCD411
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04480463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480463.